Liquid Glycerin Laxatives

Description

The product is identified by the SPL code 34089-3. No additional specific description details are provided in the available data.

Uses and Indications

This drug is indicated for the relief of occasional constipation. It typically produces a bowel movement within 15 minutes to 1 hour of administration.

Limitations of Use: There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Adults and children aged 12 years and older are advised to administer a single daily dosage of 1 suppository or as directed by a healthcare professional.

For optimal administration, the following positioning techniques are recommended:

• Left-side position: The patient should lie on their left side with the right knee bent and arms resting comfortably.

• Knee-chest position: The patient should kneel and then lower their head and chest forward until the left side of their face is resting on a surface, with the left arm folded comfortably.

When administering the laxative, it is crucial to follow these steps:

1. Preparation: Caution must be taken to remove the orange protective shield before insertion.

2. Holding the unit: The healthcare provider should hold the unit upright, grasping the bulb with fingers while using the other hand to gently pull the orange protective shield away.

3. Insertion: With steady pressure, the tip should be inserted into the rectum using a slight side-to-side movement, ensuring the tip is pointed toward the navel. It is important not to force the applicator tip into the rectum to avoid injury.

4. Facilitating insertion: Insertion may be facilitated if the patient bears down as if having a bowel movement, which helps relax the muscles around the anus.

5. Expelling the liquid: The bulb should be squeezed until nearly all liquid is expelled. While continuing to squeeze the bulb, the tip should be removed from the rectum, and the unit discarded. It is not necessary to empty the unit completely.

These instructions should be adhered to for safe and effective administration of the suppository.

Contraindications

Use of this product is contraindicated in patients experiencing abdominal pain, nausea, or vomiting unless directed by a healthcare professional.

Additionally, patients should discontinue use and seek medical advice if they experience rectal bleeding or if there is no bowel movement within one hour of administration. These symptoms may indicate a serious underlying condition that requires further evaluation.

Warnings and Precautions

The use of this product is associated with certain warnings and precautions that healthcare professionals should be aware of to ensure patient safety.

Rectal Discomfort and Usage Guidelines Patients may experience rectal discomfort or a burning sensation upon application. This product is intended for rectal use only. It is imperative that patients do not ingest the product; if swallowed, immediate medical assistance should be sought or the local Poison Control Center contacted.

Contraindications The product should not be used in the presence of abdominal pain, nausea, or vomiting unless specifically directed by a healthcare provider.

Monitoring for Serious Conditions Patients should discontinue use and consult a physician if they experience rectal bleeding or if there is no bowel movement within one hour of administration. These symptoms may indicate a serious underlying condition that requires further evaluation.

Consultation Prior to Use Healthcare professionals should advise patients to seek medical advice before using any laxative if they have experienced a sudden change in bowel habits lasting more than two weeks or if they have been using a laxative for more than one week. This precaution is essential to prevent potential complications and ensure appropriate management of bowel health.

Side Effects

Patients may experience rectal discomfort or a burning sensation as adverse reactions associated with the use of this product.

In clinical practice, it is advised that patients discontinue use and consult a healthcare professional if they encounter rectal bleeding or if there is no bowel movement within one hour of administration. These symptoms may indicate a serious underlying condition that requires medical evaluation.

Drug Interactions

No specific drug interactions have been identified in the available data. Additionally, there are no reported interactions with laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on the current information.

Packaging & NDC

Below are the non-prescription pack sizes of Liquid Glycerin Laxatives (glycerin). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 12 years and older may be prescribed a single daily dosage of 1 suppository or as directed by a healthcare professional. It is important for healthcare providers to assess individual patient needs and adjust dosages accordingly.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy.

Pregnancy

There is no specific information available regarding the use of this medication during pregnancy, including safety concerns, dosage modifications, or special precautions. Healthcare professionals should consider the lack of data when prescribing this medication to pregnant patients and weigh the potential risks and benefits. Women of childbearing potential should be counseled on the absence of established safety data and the importance of discussing any potential pregnancy with their healthcare provider.

Lactation

Nursing mothers should consult a doctor before using this product. There is a potential for excretion in breast milk, and the effects on nursing infants are not well studied; therefore, caution is advised.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of information necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in these patients to ensure safety and efficacy.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should implement supportive care measures, which may include monitoring vital signs, providing symptomatic treatment, and ensuring the patient's safety.

If available, consultation with a poison control center or a medical toxicologist is recommended to guide the management of the overdose. Additionally, healthcare professionals should refer to local protocols and guidelines for the management of overdose situations, as these may provide specific recommendations based on the substance involved.

Overall, vigilance and prompt intervention are critical in managing any suspected overdose effectively.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

Postmarketing experience has identified instances of rectal discomfort or a burning sensation associated with the use of this product. Users are advised to discontinue use and consult a healthcare professional if rectal bleeding occurs. Additionally, if no bowel movement is observed within one hour of application, it is recommended to stop using the product and seek medical advice, as these symptoms may indicate a serious condition. In cases of accidental ingestion, immediate medical assistance or contact with a Poison Control Center is advised.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the product is swallowed. It is important to inform patients that the product should not be used in the presence of abdominal pain, nausea, or vomiting unless specifically directed by a healthcare professional.

Patients should be instructed to discontinue use and consult a doctor if they experience rectal bleeding or if they do not have a bowel movement within one hour of using the product, as these symptoms may indicate a serious underlying condition.

Additionally, healthcare providers should encourage patients to consult with a doctor before using any laxative if they have experienced a sudden change in bowel habits lasting more than two weeks or if they have already been using a laxative for more than one week. This guidance is crucial to ensure the safe and effective use of the product.

Storage and Handling

The product is supplied in configurations that include specific NDC numbers. It should be stored at room temperature, ensuring that it is protected from light exposure. Freezing the product is not permitted, as it may compromise its integrity. Additionally, once opened, the product must be discarded to maintain safety and efficacy.

Additional Clinical Information

The route of administration for the product is rectal, with a recommended single daily dosage of one suppository for adults and children aged 12 years and older, or as directed by a physician.

Clinicians should counsel patients that the product is for rectal use only and should not be used in the presence of abdominal pain, nausea, or vomiting unless directed by a healthcare provider. Patients are advised to consult a doctor before using any laxative if they experience a sudden change in bowel habits lasting more than two weeks or if they have been using a laxative for more than one week. They should discontinue use and seek medical advice if rectal bleeding occurs or if there is no bowel movement within one hour of administration, as these may indicate a serious condition. In the event of accidental ingestion, patients should seek medical assistance or contact a Poison Control Center immediately.

Drug Information (PDF)

This file contains official product information for Liquid Glycerin Laxatives, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)